Table 1.
Baseline characteristics
| mFOLFOX6 or CapeOX plus bevacizumab | S-1 and irinotecan plus bevacizumab | |||
|---|---|---|---|---|
| (n = 243) |
(n = 241) |
|||
| n | (%) | n | (%) | |
| Sex | ||||
| Male | 143 | (58.8) | 151 | (62.7) |
| Female | 100 | (41.2) | 90 | (37.3) |
| PS (ECOG) | ||||
| 0 | 205 | (84.4) | 204 | (84.6) |
| 1 | 38 | (15.6) | 37 | (15.4) |
| Age | ||||
| Median [range] | 65 [29–85] | 64 [22–87] | ||
| ≥65 | 134 | (55.1) | 118 | (49.0) |
| CCr at enrollment | ||||
| Median [range] | 80.9 [60.0–153.1] | 82.7 [60.0–182.8] | ||
| ≥70 | 181 | (74.5) | 185 | (76.8) |
| Complications | ||||
| Yes | 107 | (44.0) | 108 | (44.8) |
| No | 136 | (56.0) | 133 | (52.2) |
| Adjuvant chemotherapy for colorectal cancer | ||||
| Yes | 31 | (12.8) | 32 | (13.3) |
| No | 212 | (87.2) | 209 | (86.7) |
| Differentiation assessed by histology | ||||
| Well or moderate | 212 | (87.2) | 209 | (86.7) |
| Poorly | 14 | (5.8) | 14 | (5.8) |
| Other | 17 | (7.0) | 18 | (7.5) |
| Primary lesion | ||||
| Colon | 122 | (50.2) | 130 | (53.9) |
| Rectosigmoid | 39 | (16.0) | 32 | (13.3) |
| Rectum | 82 | (33.7) | 79 | (32.8) |
| Primary lesion resection | ||||
| Yes | 164 | (67.5) | 156 | (64.7) |
| No | 79 | (32.5) | 85 | (35.3) |
| Metastatic organs | ||||
| 0–1 | 124 | (51.0) | 127 | (52.7) |
| ≥2 | 119 | (49.0) | 114 | (47.3) |
| Target lesion | ||||
| Yes | 221 | (90.9) | 214 | (88.8) |
| No | 22 | (9.1) | 27 | (11.2) |
| RAS status | ||||
| Wild type | 99 | (40.7) | 105 | (43.6) |
| Mutant type | 65 | (26.7) | 58 | (24.1) |
| Not definable | 6 | (2.5) | 3 | (1.2) |
| Missing data | 73 | (30.0) | 75 | (31.1) |
CCr, creatinine clearance.